Literature DB >> 25625345

Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats.

Lie-Chwen Lin1,2, Yu-Feng Pai1, Tung-Hu Tsai1,3,4,5.   

Abstract

Luteolin and luteolin-7-O-glucoside were isolated from the ethanolic extract of Dendranthema morifolium Ramat Tzvel. The structures of these analytes were identified by nuclear magnetic resonance ((1)H and (13)C NMR) and mass spectrometry. Ethanolic and water extracts contained luteolin-7-O-glucoside at 4.19 and 6.56%, respectively. However, the level of luteolin was only 0.19% in the ethanolic extract, and luteolin was not detected in the water extract. To examine the pharmacokinetics and bioavailability of luteolin and luteolin-7-O-glucoside in rats, parallel studies of luteolin (10 mg/kg, iv; and 100 mg/kg, po) and luteolin-7-O-glucoside (10 mg/kg, iv; and 1 g/kg, po) were conducted. The analytes were detected by high-performance liquid chromatography coupled with a photodiode array detector. A phenyl-hexyl (150 × 4.6 mm iv; 5.0 μm) column was used to separate the analytes from the biological samples. The pharmacokinetic data demonstrate that the areas under the concentration curves (AUCs) of luteolin were 261 ± 33 and 611 ± 89 (min μg/mL) after luteolin administration (10 mg/kg, iv; and 100 mg/kg, po, respectively). The oral bioavailability of luteolin was 26 ± 6%. The AUCs of luteolin-7-O-glucoside were 229 ± 15 and 2109 ± 350 (min μg/mL) after administration of luteolin-7-O-glucoside (10 mg/kg, iv; and 1 g/kg, po, respectively). The oral bioavailability of luteolin-7-O-glucoside was approximately 10 ± 2%. In the group that received luteolin-7-O-glucoside orally, a biotransformed luteolin product was detected, but this product was not detected in the group that received luteolin-7-O-glucoside intravenously. The biotransformation ratio of luteolin to luteolin-7-O-glucoside (the AUC ratio of metabolite/parent compound) was approximately 48.78 ± 0.12%. These results demonstrate that luteolin-7-O-glucoside is primarily hydrolyzed to luteolin in the gastrointestinal tract and then absorbed into the systemic circulation.

Entities:  

Keywords:  bioavailability; flavonoid; herbal medicine; pharmacokinetics; traditional Chinese medicine

Mesh:

Substances:

Year:  2015        PMID: 25625345     DOI: 10.1021/jf505848z

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.895


  21 in total

1.  Improving Oral Bioavailability of Luteolin Nanocrystals by Surface Modification of Sodium Dodecyl Sulfate.

Authors:  Jiali Liu; Yongbing Sun; Meng Cheng; Qiaoming Liu; Wan Liu; Chao Gao; Jianfang Feng; Yi Jin; Liangxing Tu
Journal:  AAPS PharmSciTech       Date:  2021-04-14       Impact factor: 3.246

Review 2.  Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.

Authors:  Yaseen Hussain; Jing Hao Cui; Haroon Khan; Michael Aschner; Gaber El-Saber Batiha; Philippe Jeandet
Journal:  Med Oncol       Date:  2021-05-05       Impact factor: 3.064

3.  Anti-oxidative, anti-secretory and anti-inflammatory activities of the extract from the root bark of Lycium chinense (Cortex Lycii) against gastric ulcer in mice.

Authors:  Hongxia Chen; Opeyemi J Olatunji; Yifeng Zhou
Journal:  J Nat Med       Date:  2016-03-14       Impact factor: 2.343

4.  Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.

Authors:  Thaise Boeing; Priscila de Souza; Silvia Speca; Lincon Bordignon Somensi; Luisa Nathália Bolda Mariano; Benhur Judah Cury; Mariana Ferreira Dos Anjos; Nara Lins Meira Quintão; Laurent Dubuqoy; Pierre Desreumax; Luisa Mota da Silva; Sérgio Faloni de Andrade
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

5.  Delivery luteolin with folacin-modified nanoparticle for glioma therapy.

Authors:  Cong Wu; Qian Xu; Xinyue Chen; Jiagang Liu
Journal:  Int J Nanomedicine       Date:  2019-09-16

6.  Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca2+-ATPase 2a.

Authors:  Wenjing Hu; Tongda Xu; Pei Wu; Defeng Pan; Junhong Chen; Jing Chen; Buchun Zhang; Hong Zhu; Dongye Li
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

7.  Inhibitory Activities of Stauntonia hexaphylla Leaf Constituents on Rat Lens Aldose Reductase and Formation of Advanced Glycation End Products and Antioxidant.

Authors:  Seung Hwan Hwang; Shin Hwa Kwon; Set Byeol Kim; Soon Sung Lim
Journal:  Biomed Res Int       Date:  2017-02-23       Impact factor: 3.411

8.  Improving anti-melanoma effect of curcumin by biodegradable nanoparticles.

Authors:  Bilan Wang; Xiaoxiao Liu; Yan Teng; Ting Yu; Junli Chen; Yuzhu Hu; Na Liu; Lingli Zhang; Yangmei Shen
Journal:  Oncotarget       Date:  2017-08-24

9.  Syntheses of mono-acylated luteolin derivatives, evaluation of their antiproliferative and radical scavenging activities and implications on their oral bioavailability.

Authors:  Stephen Lo; Euphemia Leung; Bruno Fedrizzi; David Barker
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

10.  Application of luteolin nanomicelles anti-glioma effect with improvement in vitro and in vivo.

Authors:  Songping Zheng; Yongzhong Cheng; Yan Teng; Xiaoxiao Liu; Ting Yu; Yi Wang; Jiagang Liu; Yuzhu Hu; Cong Wu; Xiang Wang; Yanhui Liu; Chao You; Xiang Gao; Yuquan Wei
Journal:  Oncotarget       Date:  2017-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.